



SN - Pd1495/21/230224

CENTRE FOR PLANT MEDICINE RESEARCH
PHARMACOLOGY & TOXICOLOGY DEPARTMENT

Product Code	Product Form	Date Received	Date Analysed	Test Conducted
Pd/024/23	Powder	10 th March, 2023	5 th June, 2023	Acute & Dermal Toxicity Test

1. ACUTE TOXICITY TEST

RESULTS:

Table Showing Results of Acute Toxicity Test on Powder (Pd/024/23) in test.

Animal Model	test
No. of Animals	test
Sex	test
No. of Groups	test
Route of Administration	test
Formulation	test
Preparation	test
Dose Administered	Apply to the affected parts twice daily
Period of Observation	test
No. of Deaths Recorded	test
Estimated Median Lethal Dose (LD ₅₀)	test
Physical Signs of Toxicity	test

REMARKS:

The LD₅₀ is estimated to be greater than 5000 mg/kg which is greater or equal to level 5 on the Hodge and Sterner Scale¹ and also 93 times more than the recommended dose (2 tablespoonful of powder into 30 ml of water once daily equivalent to 5.0 mg/kg), as indicated by the manufacturer. Thus, the product, Pd/024/23, may not be toxic and is within the accepted margin of safety (Hodge and Sterner Scale) at the recommended dose.

2. DERMAL TOXICITY TEST

PROCEDURE:

The LD₅₀ is estimated to be greater than 5000 mg/kg which is greater or equal to level 5 on the Hodge and Sterner Scale¹ and also 93 times more than the recommended dose (2 tablespoonful of powder into 30 ml of water once daily equivalent to 5.0 mg/kg), as indicated by the manufacturer. Thus, the product, Pd/024/23, may not be toxic and is within the accepted margin of safety (Hodge and Sterner Scale) at the recommended dose.

RESULTS:

The experimental SD Rat in group 1 and 2 administered with 1% and 5% w/v of the Powder intradermally and topically (0.5-1 g), showed no ulceration, irritation and/or inflammations at the site of injection and shaved area, respectively.

REMARKS:

Pd/024/23 appears to be safe when applied to the skin.

Analysed by



Mr. Pharm System
Admin
Reseach Officer

Approved by



Mr. Pharm System
Admin
Reseach Officer

